Bristol Myers Squibb and Nektar Therapeutics are ending an immunotherapy partnership, announcing Thursday they will cease all work pairing Bristol Myers' Opdivo with an experimental Nektar drug following setbacks in kidney and bladder cancer. The announcement comes one month after the combination also failed in melanoma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,